Bluebird Bio, INC 8-K filings

Gene therapy pioneer bluebird bio has completed its acquisition by investment firms Carlyle and SK Capital, transitioning to a privately held company with new leadership and significant capital backing to scale its commercial operations.

Bluebird Bio has amended its merger agreement with Carlyle and SK Capital, providing stockholders the option to receive either $3.00 per share plus a contingent value right (CVR) of $6.84, or $5.00 per share in cash.

Bluebird Bio has received an unsolicited, non-binding acquisition proposal from Ayrmid Ltd, offering $4.50 per share in cash plus a $6.84 contingent value right, while the company is already subject to a merger agreement with Carlyle and SK Capital Partners.

Bluebird Bio enters a definitive agreement to be acquired by Carlyle and SK Capital, offering stockholders $3.00 per share in cash plus a contingent value right of $6.84 per share upon achieving a net sales milestone.

Bluebird Bio has terminated its sublease agreement with Aventis and sub-sublease agreement with Meta Platforms for space in Cambridge, Massachusetts, effective immediately.

Bluebird Bio has completed a 1-for-20 reverse stock split, effective December 12, 2024, to consolidate its shares and adjust its trading price.

Bluebird Bio has finalized a 1-for-20 reverse stock split, set to take effect on December 12, 2024, after receiving shareholder approval.

Bluebird Bio announced its third quarter 2024 financial results, highlighting commercial momentum with increased patient starts and providing revenue guidance for the fourth quarter.

Bluebird Bio's annual meeting saw stockholders approve an increase in shares for the incentive plan and elect three directors, while a proposal for officer exculpation was rejected and a vote on a reverse stock split was adjourned.

Bluebird Bio has received a notice from Nasdaq for failing to maintain a minimum share price of $1, putting its listing at risk.

Bluebird Bio is implementing a restructuring plan, including a 25% workforce reduction, to cut operating expenses by 20% and achieve cash flow break-even by the second half of 2025.

Bluebird Bio has entered into a new five-year manufacturing agreement with Henogen for the production of lentiviral vector used in its gene therapy product, LYFGENIA.

Bluebird Bio has amended its loan agreement to extend deadlines for filing its 2023 annual report and Q1 2024 quarterly report, avoiding a potential violation of loan covenants.

Bluebird Bio has received further notices from Nasdaq regarding delays in filing its quarterly reports, adding to previous concerns about its annual report.

Bluebird Bio has amended its loan agreement with Hercules Capital, modifying milestone requirements for accessing additional funding tranches and adjusting warrant terms.

Bluebird Bio has amended its loan agreement to extend deadlines for providing financial reports and avoid covenant violations related to late filings.

Bluebird Bio has appointed Michael Cloonan to its Board of Directors, effective June 20, 2024, with associated compensation including stock options and restricted stock units.

Bluebird Bio has announced the appointment of O. James Sterling as its new Chief Financial Officer, effective June 10, 2024, following the departure of Christopher Krawtschuk.

Bluebird Bio announced its first quarter 2024 financial results, highlighted by $18.6 million in net revenue and the first patient start for LYFGENIA, while also providing 2024 guidance.

Bluebird Bio has amended its loan agreement with Hercules Capital to address delays in filing its 2023 annual report and Q1 2024 quarterly report due to financial restatements.

Bluebird Bio has received a notification from Nasdaq for not filing its 2023 annual report on time, requiring a plan to regain compliance.

Bluebird Bio has announced a further delay in filing its 2023 annual report and first quarter 2024 report due to ongoing restatement work related to lease accounting.

Bluebird Bio reported its 2023 financial results, highlighted operational progress, announced a restatement of prior financials due to accounting errors, and secured a $175 million loan to extend its cash runway.

Bluebird Bio has entered into a loan agreement for up to $175 million to support the commercialization of its gene therapies.